Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S132-8
Date
01/18/2012Pubmed ID
22226097DOI
10.1016/j.bbmt.2011.11.018Scopus ID
2-s2.0-84855413280 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
Over the past decade, numerous advances have been made in elucidating the biology of and improving treatment for chronic lymphocytic leukemia (CLL). These studies have led to identification of select CLL patient groups that generally have short survival dating from time of treatment or initial disease relapse who benefit from more aggressive therapeutic interventions. Allogeneic transplantation represents the only potentially curative option for CLL, but fully ablative regimens applied in the past have been associated with significant morbidity and mortality. Reduced-intensity preparative regimens has made application of allogeneic transplant to CLL patients much more feasible and increased the number of patients proceeding to this modality. Arising from this has been establishment of guidelines where allogeneic stem cell transplantation should be considered in CLL. Introduction of new targeted therapies with less morbidity, which can produce durable remissions has the potential to redefine where transplantation is initiated in CLL. This review briefly summarizes the field of allogeneic stem cell transplant in CLL and the interface of new therapeutics with this modality.
Author List
Jaglowski SM, Byrd JCAuthor
Samantha M. Jaglowski MD, MPH Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Disease-Free SurvivalFemale
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Stem Cell Transplantation
Survival Rate
Transplantation Conditioning
Transplantation, Homologous
